() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: PreveCeutical

PreveCeutical Granted Approval to Acquire and Use Human Mucosal Tissue for Final Phase of Sol-Gel Program

PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces that the Company’s research team at the University of Queensland has been granted the necessary approvals from a local hospital’s Human Ethics Committee to acquire and use human nasal mucosal tissue (mucosal membrane) for the final phase of the cannabinoid-based, soluble gel (“Sol-gel”) drug delivery research and development program (the “Sol-gel Program”).
Read more

PreveCeutical Announces Default Judgment Against JCN Capital Corp.

PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces that it has obtained a default judgement against JCN Capital Corp. (“JCN”) in connection with a Supreme Court of British Columbia action (the “Action”). The Action was brought by PreveCeutical in December 2018, against a group of defendants (the “Defendants”) for fraudulent misrepresentation, breach of contract, conspiracy, unjust enrichment and breach of duty of honest performance in connection with services that the Defendants failed to provide to PreveCeutical, and various consulting agreements and subscription agreements entered into between PreveCeutical and certain of the Defendants (see news release dated January 7, 2019).
Read more